EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis

Jian Xu iD, Dongshuo Li, Jinghua Shi, Bin Wang, Fei Ge, Zhenyong Guo, Xiaopan Mu, Eric Nuermberger iD, Yu Lu iD

Antimicrobial Agents and Chemotherapy · 2023

DOI: 10.1128/aac.01532-22 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Jian Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, and Beijing Chest Hospit…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Beijing Municipality, MOST | National Natural Science Foundation of China, Tongzhou High-level talents Development Support Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bedaquiline (BDQ) is an effective drug for the treatment of drug-resistant tuberculosis. Mutations in atpE , which encodes the target of BDQ, are associated with large increases in MICs. Mutations in Rv0678 that derepress the transcription of the MmpL5-MmpS5 efflux transporter are associated with smaller increases in MICs. However, Rv0678 mutations are the most common mutations that are associated with BDQ resistance in clinical isolates, and they also confer cross-resistance to clofazimine (CFZ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantHumansProteomeAntitubercular AgentsDiarylquinolinesClofazimineMutationMicrobial Sensitivity Tests

Stichwörter der Autor:innen

Mycobacterium tuberculosisRv0678atpEbedaquilineexposureproteomeresistance

Substanzen

ProteomeAntitubercular AgentsDiarylquinolinesClofazimine

Autor:innen und Institutionen

  • Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, and Beijing Chest Hospital, Capital Medical University, Beijing, China.
  • Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

ORCID-Profile: Jian Xu, Eric Nuermberger, Yu Lu

Förderung

  • Natural Science Foundation of Beijing Municipality
  • MOST | National Natural Science Foundation of China
  • Tongzhou High-level talents Development Support Plan
  • Beijing Hospital Authority

Zitieren

APA

Xu, J., Li, D., Shi, J., Wang, B., Ge, F., Guo, Z., Mu, X., Nuermberger, E., & Lu, Y. (2023). Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01532-22

Vancouver

Xu J, Li D, Shi J, Wang B, Ge F, Guo Z, et al. Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.01532-22

BibTeX
@article{Xu2023,
  author = {Xu, Jian and Li, Dongshuo and Shi, Jinghua and Wang, Bin and Ge, Fei and Guo, Zhenyong and Mu, Xiaopan and Nuermberger, Eric and Lu, Yu},
  title = {Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  doi = {10.1128/aac.01532-22}
}
Kostenlos starten →